OTC · Medical - Diagnostics & Research

Cellbxhealth PLC (ANPCF) Stock

$0.02 +0.00% OTC: ANPCF Healthcare

CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions.

Valuation

MetricValue
Price$0.02
Market Cap$6.53M
P/E Ratio-0.33
P/B Ratio0.93
P/S Ratio3.27
EPS (TTM)$-0.06
52-Week High$0.11
52-Week Low$0.01
Dividend Yield—

Financials & Margins

MetricValue
ROE-285.71%
ROA-153.85%
ROCE-222.22%
Gross Margin-354.63%
Operating Margin-2000.00%
Net Margin-2000.00%
Debt/Equity0.25
Current Ratio2.76

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$2.0M$3.0M$1.0M
Operating Profit$-17.0M$-24.0M$-22.0M$-15.0M$-20.0M
Net Profit$-15.0M$-22.0M$-20.0M$-14.0M$-20.0M
EPS$-0.07$-0.09$-0.08$-0.05$-0.06
Op Margin-1701.4%-2325.4%-995.4%-527.5%-1495.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$47.0M$50.0M$31.0M$25.0M$13.0M
Total Liabilities$7.0M$10.0M$8.0M$7.0M$5.0M
Cash$32.0M$32.0M$16.0M$10.0M$7.0M
Borrowings$2.0M$5.0M$5.0M$4.0M$2.0M

Latest News

CelLBxHealth, Coiled Therapeutics, Genflow, Bradda Head Lithium, Quantum Helium, Quantum Blockchain Proactive · Aug 3, 2026 London BTC Company, CelLBxHealth, Anglo Asian Mining, Galliford Try, NextEnergy Solar Fund Proactive · Jul 15, 2026 ACG Metals, Rockfire Resources, Sunda Energy, CelLBxHealth, Poolbeg Pharmaceutical Proactive · Jul 14, 2026 Solvonis Therapeutics, Tertiary Minerals, CelLBxHealth, Coinsilium, Eco Buildings, Frontier IP Proactive · Jun 26, 2026 CelLBxHealth PLC (ANPCF) Full Year 2025 Earnings Call Highlights: Strategic Partnerships and ... GuruFocus.com · Jun 24, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-16.0M$-14.0M$-13.0M$-9.0M
Investing Cash Flow$13.0M$-4.0M$-1.0M$0$0
Financing Cash Flow$0$0$0$0$-1.0M
Net Cash Flow$20.0M$0$-16.0M$-6.0M$-2.0M
Free Cash Flow$-16.0M$-18.0M$-15.0M$-14.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-137.88%
Quick Ratio2.41
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held5.69%
Institutions Held33.30%
Institutions Float Held35.30%
Institutional HolderSharesReport Date
JNL Series Trust-JNL Multi-Manager International Small Cap Fund1,035,6692025-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CMHSFComprehensive Healthcare Systems, Inc. $0.29 +0.00% -2.17 $5.31M 0.00%
CNFHFCanaFarma Hemp Products Corp. $0.00 — 0.00 $19561 0.00%
IMTHAnTix Holdings, Inc. $0.00 — 0.02 $98914 0.00%
LIANYLianBio $0.07 -12.50% 1.56 $7.64M 6.14%
NGMDFNuGen Medical Devices Inc. $0.02 +0.00% -0.45 $3.55M 0.00%

About Cellbxhealth PLC

CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions. Its core offerings include the Parsortix PC1 and PR1 systems, which are innovative medical devices engineered to capture and retrieve intact circulating tumor cells (CTCs) from patient blood. Specifically, the PC1 system is designed for metastatic breast cancer samples, facilitating subsequent user-validated downstream analysis. CelLBxHealth also provides the Portrait+ CTC Staining kit, a laboratory solution for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs with high analytical sensitivity and specificity, alongside the CellKeep Slide technology for CTC harvesting. In addition to these products, the company delivers a suite of laboratory services, including CTC enrichment and liquid biopsy analysis. Specialized assays are also available, such as Portrait Flex for immunofluorescence-based identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, Portrait PD-L1 for CTC evaluation, and bespoke custom CTC assays. Furthermore, CelLBxHealth plc has forged strategic alliances, including a partnership with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. for the application of its pan-cancer next-generation sequencing (NGS) panel.

Cellbxhealth PLC is headquartered in GB.

Cellbxhealth PLC (ANPCF) stock trades at $0.02 with a market capitalization of $6.53M. The stock is valued at a price-to-earnings (P/E) ratio of -0.33, price-to-book of 0.93, price-to-sales of 3.27. Over the past 52 weeks the stock has ranged between $0.01 and $0.11, and currently trades 81.8% below its 52-week high.

On profitability, Cellbxhealth PLC generates a return on equity (ROE) of -285.71%, return on capital employed of -222.22%, an operating margin of -2000.00%, a net profit margin of -2000.00%.

Official website: cellbxhealth.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides